MedTrace Logo

Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection

NCT01884948 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2014-06-04

No results posted yet for this study

Summary

To study the efficacy and safety of intravenous Omegaven™ (vs. Placebo) in reducing postoperative morbidity and mortality after major liver resection.

Conditions

  • Major Liver Surgery

Interventions

DRUG

Omegaven™

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Pierre Alain Clavien, MD PhD · University Hospital Zurich, Visceral and Transplantation Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884948 on ClinicalTrials.gov